AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Lumoxiti, Enhertu, Faslodex, Zoladex, Iressa, Arimidex, Casodex/Cosudex, and other products for oncology diseases; and Brilinta/Brilique, Farxiga/Forxiga, Bydureon, Onglyza, Byetta, Symlin, Qtern, Lokelma, Crestor, Seloken/Toprol-XL, Atacand1/Atacand HCT/Atacand Plus, Kombiglyze XR, Komboglyze, Xigduo/Xigduo XR, and other products for cardiovascular, renal, and metabolism diseases.
The company's marketed products also comprise Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi Aerosphere, Breztri Aerosphere, and other products for respiratory diseases; Synagis and Fluenz Tetra/FluMist Quadrivalen for infections; Seroquel IR/Seroquel XR, Movantik/Moventi and Vimovo for neuroscience diseases; Nexium and Losec/Prilosec for gastroenterology diseases. It serves primary care and specialty care physicians through distributors and local representative offices.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.